What does ArkBio’s AK0406 dosing milestone mean for long-acting influenza prevention?
ArkBio has dosed all Phase I cohorts of AK0406, moving the long-acting influenza prophylaxis candidate into six-month safety follow-up.
Pharma & Biotech
Medical Devices & Diagnostics
Visby Medical’s FDA-cleared at-home PCR could reshape flu and COVID-19 testing
Discover how Visby Medical’s FDA-cleared at-home PCR could reshape flu and COVID-19 testing, treatment access, and diagnostics competition.
Pharma & Biotech
Can functional logic beat genetic drift? MindWalk’s bet on influenza physics
MindWalk says flu can’t mutate past this. Find out how its HYFT AI platform found a functional constraint that may redefine universal vaccine design.